Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s mRNA engineering technology platform VERSagile and lead therapeutic candidate VMB-100 at the BIO Asia-Taiwan Conference, taking place on 27-31 July 2022 in Taiwan. Read more…
Optimum Strategic Communications is pleased to support Versameb during World Continence Week, a company raising awareness of the high unmet medical need of patients suffering with Stress Urinary Incontinence (SUI) and continence related issues which impacts the lives of millions of patients worldwide. Versameb’s Chief Executive Officer, Klaas Zuideveld to present on the Company’s proprietary […]
Lead therapeutic candidate has the potential to treat Stress Urinary Incontinence Raising awareness of the high unmet medical need of patients Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, is pleased to announce that Chief Executive Officer Klaas Zuideveld and Clinical Advisor Prof. Roger Dmochowski will be presenting Versameb’s lead therapeutic candidate, […]
Presentation demonstrates lead therapeutic candidate VMB-100 has the potential to address the unmet medical needs of patients suffering from Stress Urinary Incontinence Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the RNA Leaders World Congress, taking place on the 16-17th […]
Appointment of experts to support development of lead candidate VMB-100, an RNA-based therapy for Stress Urinary Incontinence Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces the formation of an Advisory Board comprised of industry leaders in urology. These include Professor Roger Dmochowski of Vanderbilt University, Professor Margot Damaser of the […]
